Inhibition of CDK2 and CDK4/6 functions has been found to suppress the growth of triple negative breast cancer cells (TNBC), which manifests itself in loss of expression of the RB protein, or high expression of cyclin E, which are thought to confer resistance to treatment with CDK4/6 inhibitors. Here, CDK4 is linked to triple-negative breast carcinoma.